TargetB-cell lymphoma 6 protein/B-cell lymphoma 6 protein [32-99]/Nuclear receptor corepressor 2(Homo sapiens (Human))
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataIC50: 900nMAssay Description:This assay is used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding ...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein/B-cell lymphoma 6 protein [32-99]/Nuclear receptor corepressor 2(Homo sapiens (Human))
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataIC50: 1.20E+3nMAssay Description:This assay is used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding ...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein/B-cell lymphoma 6 protein [32-99]/Nuclear receptor corepressor 2(Homo sapiens (Human))
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataIC50: 1.60E+3nMAssay Description:This assay is used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding ...More data for this Ligand-Target Pair
TargetB-cell lymphoma 6 protein/B-cell lymphoma 6 protein [32-99]/Nuclear receptor corepressor 2(Homo sapiens (Human))
Ontario Institute For Cancer Research (Oicr)
US Patent
Ontario Institute For Cancer Research (Oicr)
US Patent
Affinity DataIC50: 1.80E+3nMAssay Description:This assay is used to determine whether compounds inhibit the interaction between the BTB domain of BCL6 and a peptide derived from the BCL6 binding ...More data for this Ligand-Target Pair